Extending the Cure

The Extending the Cure project is a research and consultative effort that frames the growing problem of antibiotic resistance as a challenge in managing a shared societal resource. The inaugural report of Extending the Cure provides an objective evaluation of a number of policies to encourage patients, health care providers, and managed care organizations to make better use of existing antibiotics and to give pharmaceutical firms greater incentives to both develop new antibiotics and care about resistance to existing drugs. It sets the stage for continued research to prevent the impending health crisis of widespread antibiotic resistance.


The Extending the Cure project is funded in part by the Robert Wood Johnson Foundation through its Pioneer Portfolio, which supports innovative projects that may lead to breakthrough improvements in health and health care.


WASHINGTON, D.C. Infections caused by a type of antibiotic-resistant bacteria are increasing among children in the U.S., according to a ...

Today CDDEP is excited to release a new video on antibiotic resistance: Unstoppable Superbugs: Closer Than We Think? 


A number of Extending the Cure studies have highlighted the changing epidemiology of methicillin-resistant S. aureus (MRSA): first, we noted the emergence of community strains (CA-MRSA) and...

The growth of MRSA-related hospitalizations was stagnant between 2005 and 2009; Community-associated infections peak in the summer, likely due to seasonal antibiotic overuse....



Adverse reactions (AR) to antibiotics are common among outpatients, accounting for ~20% of drug-related AR visits to emergency rooms. Little is known about the prevalence of ARs among inpatients. This retrospective study describes patient-reported antibiotic allergies on admission, their effect on outcome, and ARs associated with antibiotic use in 6 acute care facilities of varying size and location.
The infographic summarizes our latest findings from the interactive ResistanceMap visualizations on the alarming  trends in drug resistance and regional use of antibiotics between 1999 and 2010.  Download print materials here:
Gonorrhea (Neisseria gonorrhoeae)is the second most frequently reported infectious disease in the United States. Consequences of untreated gonococcal infections include pelvic inflammatory disease and infertility. Fluoroquinolones such as ciprofloxacin or levofloxacin were widely used to treat gonorrhea in the 1990s, but rising resistance prompted the CDC to advise against their use in 2007.
Outpatient antibiotic use is a key driver of antibiotic resistance. Previous research has highlighted the peak of prescribing during flu season, as well as the geographic link between high annual rates of antibiotic consumption and pneumococcal resistance to macrolides. However, little is known about the month-to-month seasonal relationship between use and resistance. 
This infographic shows the burden of two healthcare associated infections (HAIs) in the United States in 2006. Pneumonia and sepsis, a bacterial infection that overwhelms the bloodstream, were associated with 2.3 million excess patient days, $8.1 billion added healthcare costs, and 43,000 avoidable deaths.